Company Overview and News

 
Royal Gold: Still One Of The Strongest Streaming Companies

2018-05-23 seekingalpha
Pascua-Lama seems to be a dud, delays at Mt Milligan will be felt in the next two quarters, but New Gold's Rainy River will soften the blow.

3
Top 20 Gold Stocks to Buy Despite Irrational Markets

2018-05-21 investorplace
Although the markets have their own logic, highly capitalized gold-mining companies seemingly should belong on any “stocks to buy” list. Thanks to rising geopolitical tensions and soaring trading sentiment, many folks seek safe-haven assets. While gold stocks seemingly offer a viable solution, their overall performance has been unusually disappointing.

 
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of May 14

2018-05-13 seekingalpha
After an extremely busy week last week, there are only two Canadian Dividend All-Stars scheduled to report earnings this coming week. Unfortunately, neither are expected to increase dividends. However, we have plenty to catch up on from last week before banks start to report in two weeks.

 
Midas Gold Could Be Acquired For A Generous Premium In The Next 18 To 24 Months

2018-05-07 seekingalpha
There is a mineral found in Stibnite that may be a strategic asset for the U.S. in its impending trade war with China.

 
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of May 7

2018-05-06 seekingalpha
Strap yourselves in, it is going to be a very busy week. It will be one of the busiest weeks of the year as there are 35 Canadian Dividend All-Stars scheduled to report earnings this coming week. The great news is that investors can also expect a slew of dividend raises this week. Before we dive into the coming week, let’s take a look at last week’s results.

1
Eldorado Gold: Key Takeaways From Q1 Results

2018-04-27 seekingalpha
Eldorado Gold posted a gain of $8.718 million, or $0.01 per share, for the first quarter. Revenues were $131.91 million up 17.9% from a year ago and up 30% sequentially.

 
How Have Miners’ Correlations with Gold Been Moving in 2018?

2018-04-20 marketrealist
In this part of our series, we’ll be looking at the correlation between gold and four mining stocks: New Gold (NGD), Newmont Mining (NEM), Franco-Nevada (FNV), and Randgold Resources (GOLD). Mining stocks mostly move with gold prices but not always. Among these four miners, Newmont has shown the highest correlation to gold, while Franco Nevada has seen the lowest correlation on a YTD (year-to-date) basis.

1
3 Gold Mining Stocks That Are Waking Up

2018-04-16 investorplace
Gold stocks are percolating. And while much work remains before their long-term technicals turn bullish, the whole sector could be worth a trade here.

2
Wheaton Precious Metals: What To Do Now

2018-04-09 seekingalpha
It was a strong quarter for the gold & silver streamer, but a disappointing year overall.

 
GDX: Risk On, Game On!

2018-04-08 seekingalpha
Will Gold Miners with the best exposure to precious metals turn out to be one of the market winners in 2018?

 
Sell Victoria Gold After The Construction Financing

2018-03-27 seekingalpha
Victoria Gold (OTCPK:VITFF) has been hailed as the next Yukon takeover target ever since Kaminal Gold was acquired by Goldcorp (GG) in 2016. The C$500M construction financing package announced for the Eagle gold project on March 8 has effectively put an end to this takeover speculation and has put Victoria Gold on a path to becoming an independent gold producer within a couple of years.

 
Gold Comes Come Back Into Favor As Volatility Soars In 2018

2018-02-16 seekingalpha
Don't forget forty year cycle for gold rushes we may be on the verge of the next one!

1
Gold Mining Bull: Top News And Month In Review

2018-01-31 seekingalpha
It has been a great month for gold and gold miners, but this is not all that surprising given gold's seasonal strength in January.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...